Last reviewed · How we verify
verapamil plus lithium
Verapamil (a calcium channel blocker) combined with lithium (a mood stabilizer) works synergistically to modulate cardiac conduction and neuronal signaling pathways.
Verapamil (a calcium channel blocker) combined with lithium (a mood stabilizer) works synergistically to modulate cardiac conduction and neuronal signaling pathways. Used for Bipolar disorder with cardiac arrhythmia or rate control requirement (investigational).
At a glance
| Generic name | verapamil plus lithium |
|---|---|
| Sponsor | University of Pittsburgh |
| Drug class | Combination therapy (calcium channel blocker + mood stabilizer) |
| Target | L-type calcium channels (verapamil); inositol monophosphatase and GSK-3 (lithium) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Cardiology (indication-dependent) |
| Phase | Phase 3 |
Mechanism of action
Verapamil blocks L-type calcium channels in cardiac and vascular tissue, slowing conduction and reducing contractility. Lithium inhibits inositol monophosphatase and glycogen synthase kinase-3, affecting intracellular signaling and neuroprotection. The combination may provide enhanced therapeutic effects in conditions requiring both cardiac rate control and neuropsychiatric stabilization, though the exact synergistic mechanism in this Phase 3 context requires clarification of the specific indication.
Approved indications
- Bipolar disorder with cardiac arrhythmia or rate control requirement (investigational)
Common side effects
- Tremor
- Polyuria/polydipsia
- Constipation
- Dizziness
- Lithium toxicity (at elevated levels)
- Bradycardia
Key clinical trials
- Normothermic Machine Perfusion (NMP) Versus Hypothermic Machine Perfusion (HMP) in Human Kidney Transplantation (NA)
- Pharmacotherapy of Treatment-Resistant Mania (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- verapamil plus lithium CI brief — competitive landscape report
- verapamil plus lithium updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI